

复方活脑舒胶囊

注射用磷酸川芎嗪

Ligustrazine Phosphate for Injection

【用法】用于缺血性脑血管疾病
如脑出血、脑梗死、脑栓塞、蛛网膜下腔出血等。

依达拉奉注射液
Edaravone Injection

国药准字H2008

血脉清片

XUE MAI QING



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(於中華人民共和國註冊成立之股份有限公司)

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(股份代號：8049)

(Stock Code : 8049)

2021

Environmental,
Social and Governance Report
環境、社會及管治報告

海昆肾喜胶囊

Hai Kun Shen Xi Jiao Nang

国药准字 Z20030402

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

環境、社會及管治報告



ABOUT THE REPORT

Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “Company”) and its subsidiaries (collectively referred to as the “Group”) is committed to the long-term sustainability of its businesses and the communities with which it engages. The Group pursues this business approach by managing its businesses prudently and executing management decisions with due care and attention. In addition, the Group is committed to improving its environmental, social and governance (“ESG”) performance by upholding good corporate governance standards, protecting the environment, engaging the community and promoting social integration.

Scope of the ESG Report

This ESG report (the “ESG Report”) discloses the Group’s ESG management approach and performance during the financial year from 1 January 2021 to 31 December 2021 (the “Reporting Period”) and explains how the Group complies with the “comply or explain” provisions of the Environmental, Social and Governance Reporting Guide (“ESG Reporting Guide”) in Appendix 20 to the Rules Governing the Listing of Securities (the “Listing Rules”) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

Reporting Principles

- **Materiality** – Materiality assessment was conducted to diagnose material issues during the Reporting Period. Materiality of issues was reviewed by the board of directors (“Board” or “Board of Directors”) of the Company and senior management of the Group.
- **Quantitative** – The standards and methodologies used in the calculation of relevant data, as well as the assumptions used were disclosed in this ESG Report.
- **Consistency** – The preparation of this ESG Report was substantially consistent with the previous year. Explanations were provided regarding data with changes in the scope of disclosure and calculation methodologies.
- **Balance** – This ESG Report aims to disclose data in an objective way, which aims to provide stakeholders with a balance overview of the Group’s overall ESG performance.

BUSINESS OVERVIEW

The Group is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. There were no changes in the nature of the Group’s principal activities during the year.

關於本報告

吉林省輝南長龍生化藥業股份有限公司(「本公司」)及其附屬公司(合稱「本集團」)致力於業務及業務經營所在社區的長遠可持續發展。本集團所追求的經營方針是審慎管理業務，並盡責專注地執行管理決策。此外，本集團亦致力遵守良好的企業管治標準、保護環境、促進社區參與及宣揚社會融合，從而改善其環境、社會及管治績效。

環境、社會及管治報告範圍

本環境、社會及管治報告(「本ESG報告」)披露本集團於二零二一年一月一日至二零二一年十二月三十一日財政年度(「報告期間」)的環境、社會及管治管理方針及績效，以及闡釋本集團如何遵守香港聯合交易所有限公司(「聯交所」)證券上市規則(「上市規則」)附錄二十《環境、社會及管治報告指引》(「ESG報告指引」)所載的「不遵守就解釋」條文。

報告原則

- **重要性** — 重要性評估旨在識別於報告期間內的重要事項。事項的重要性經由本公司董事會(「董事會」)及本集團高級管理層審閱。
- **定量** — 於本環境、社會及管治報告內披露計算相關數據時使用的準則及方法，以及所用的假設。
- **一致性** — 本環境、社會及管治報告的編製大致與上一年度一致。關於披露範圍及計算方法變動所涉數據均作解釋。
- **平衡** — 本ESG報告旨在以客觀方式披露數據，以期為持份者提供本集團整體環境、社會及管治績效的平衡概覽。

業務概覽

本集團業務主要在中國製造及分銷長龍和清通品牌中藥及醫藥產品。本集團的主要業務性質於本年度期間並無改變。



STAKEHOLDERS' ENGAGEMENT

In order to define the current and future sustainability strategies, it is important to understand stakeholders' perspectives and expectations on the development and success of the Group and help assess the potential impacts of the future business activities.

The Group will continue to establish effective communication with the major stakeholders in various ways in order to deal with their concerns and provide feedback in a timely manner. It is believed that it is necessary to consider the needs of all stakeholders, which is conducive to maintaining a long-term friendly relationship with shareholders and investors, employees, customers and public bodies. The areas of expectations considered by the stakeholders are listed below:

持份者參與

為釐定當前及未來可持續發展政策，了解持份者對本集團發展及成功的觀點及預期，以及協助評估未來業務活動的潛在影響至關重要。

本集團將繼續循不同渠道與主要持份者建立有效溝通，以適時處理彼等的關注事項及給予反饋。本集團相信有必要顧及所有持份者的需要，有利維持與股東及投資者、僱員、客戶及公共團體的長期友好關係。持份者考慮的期望範疇載列如下：

Category 議題範疇	Issues 議題名稱
Environmental Protection 環境保護	1. Greenhouse gases and air emission management 溫室氣體及空氣污染物
	2. Waste management 廢棄物管理
	3. Use of energy 能源使用
	4. Water use efficiency and sewage management 用水效益及污水管理
	5. The environment and natural resources management 環境及天然資源
Employee Care 僱員關懷	6. Employment management system 僱傭管理制度
	7. Diversity, equal opportunity and eliminating discrimination 多元化、平等機會和反歧視
	8. Occupational health and safety 職業健康與安全
	9. Training and development 培訓與發展
	10. Labour standards 勞工準則

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

環境、社會及管治報告



Category 議題範疇	Issues 議題名稱
Operating Responsibilities 運營責任	<ul style="list-style-type: none">11. Supply chain management 供應鏈管理12. Supply chain environmental and social risk management 供應鏈環境及社會風險管理13. Product and service quality management 產品及服務質量管理14. Fair and responsible marketing 公平和負責任的營銷15. Protecting customer privacy 保障客戶資料隱私16. Anti-corruption 反貪污
Community Investment 社區投資	<ul style="list-style-type: none">17. Understanding the needs of the community 瞭解社區需要18. Supporting community development 支持社區發展

With respect to this ESG Report, the Group identified quality of work environment and product and service responsibility as issues of the highest importance to its stakeholders and the Group. This review has helped the Group to prioritise its corresponding sustainability issues and highlight the material and relevant aspects so as to align them with stakeholders' expectations.

就本ESG報告而言，本集團已識別工作環境的質素以及產品及服務責任為對其持份者及本集團最為重要事項。此審閱有助本集團將其相應的可持續發展事項排序及指出重要及相關層面，以符合持份者的期望。

COMMENTS AND FEEDBACK

This ESG Report is available and can be downloaded from the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.jlchanglong.com). In the meantime, your feedback regarding the review and its overall sustainability practices is welcomed. The Company's contact details are as follows:

Room 1101-2, 11/F
Office Tower Two, Grand Plaza
625 & 639 Nathan Road
Mong Kok, Kowloon
Hong Kong
Telephone: 86-0435-8218333
Fax: 86-0435-8210005
Email: contactus@jlchanglong.com

意見及反饋

本ESG報告可於聯交所網站(www.hkexnews.hk)及本公司網站(www.jlchanglong.com)查閱及下載。本集團亦歡迎閣下對回顧檢討及本集團整體可持續發展常規提出意見。本公司的聯絡資料詳列如下：

香港
九龍旺角
彌敦道625及639號
雅蘭中心辦公樓二期
11樓1101-2室
電話：86-0435-8218333
傳真：86-0435-8210005
電郵：contactus@jlchanglong.com

For the year ended 31 December 2021, the Group has complied with the “comply or explain” provisions set out in the Environmental, Social and Governance Reporting Guide contained in Appendix 20 to the GEM Listing Rules and the relevant information is set out below.

A. ENVIRONMENT

1. Emissions

The major raw materials used by the Group in production are various kinds of Chinese herbal medicines and their production and operation may have a minor effect on the environment and the natural resources. The Group actively fulfils its social responsibilities, always adheres to the concept that development and environmental protection are equally important and makes rational use of various resources to protect the environment. The Group strictly complies with the provisions of the Environmental Protection Law of the People's Republic of China so as to achieve saving energy and consumption reduction, lowering discharges and improving efficiency, and try our best to minimize the impact that the production and operation process have on the ecosystem.

2. Use of resources

The Group also advocates the concept of green production so as to achieve the target of energy saving, consumption lowering and discharge reduction. The Group saved various kinds of resources by optimising the technological process, enhancing the technology standard, using LED energy-saving lighting and cutting down water consumption during the production process. Moreover, with respect to the protection and recycling of water resources, the Group adopted a recycle system throughout the production process so as to reduce the amount of water resources used.

During the year ended 31 December 2021, the Group's consumption in electricity, coal and water were:

Electricity:	6,490,000 kWh
Coal:	16,820 Tonnes
Water:	157,740 Tonnes

3. Environment and natural resources

The Group pursues the best practice between the development and the environment, and takes into careful consideration of all the aspects and activities within the value chain to mitigate the impact on the environment. To achieve the sustainable development of the environment, the Group regularly provides environmental protection information and practical advice related to environmentally friendly living style to staff for circulation.

截至二零二一年十二月三十一日止年度，本集團已遵守GEM上市規則附錄二十所載《環境、社會及管治報告指引》載列的「不遵守就解釋」條文，有關資料如下所述。

A. 環境

1. 排放物

本集團用於生產的主要原材料為各類中草藥，其生產經營對於環境及天然資源或有輕微影響。本集團積極履行社會責任，始終堅持發展與環境保護並重的理念，合理利用各類資源，以實際行動踐行環境保護。本集團嚴格遵照《中華人民共和國環境保護法》等相關制度，進一步達到節能降耗、減污增效的目的，盡可能將生產經營過程中對生態系統造成的影響降至最低。

2. 資源使用

本集團亦倡導綠色生產理念，達到節能、降耗、減污的目的。本集團在生產過程中通過完善工藝流程、提升技術含量，亦採取LED節能照明、節約用水等措施，節約各類資源。同時，在水資源保護及再利用上，本集團生產環節均採用循環水系統，以減少水資源的使用量。

於截至二零二一年十二月三十一日止年度，本集團耗電，耗煤及耗水量為：

電力：	6,490,000千瓦時
煤炭：	16,820公噸
水：	157,740公噸

3. 環境及天然資源

本集團追求與環境的最佳實務，以及對價值鏈內的各個營運方面及活動作出謹慎考慮，減低對環境的影響。為達成環境可持續發展，本集團定期向員工傳閱環保訊息及有關環保生活方式的實用建議。



B. SOCIETY

Employment and labor practices

1. Employment

Employees are regarded as the greatest and most valuable assets and core competitive advantages of the Group who continuously provide the source of innovation for the Group. The Group offers competitive remuneration and welfare, and implements comprehensive performance appraisal scheme to award and praise the staff with excellent performance and assists them with their career development and promotion within the Group by providing appropriate trainings and opportunities. Meanwhile, in order to create a favorable and fair working environment for employees and protect their physical and psychological health, the Group will give careful consideration to all the valuable suggestions for improving the working efficiency and harmonizing the working atmosphere proposed by employees, thereby establishing a united, harmonious and professional team for the Group.

The Group strictly complied with the regulations and provisions of laws in the PRC and Hong Kong, formulated and strictly implemented the relevant management system and measures, and expressly specified the employment, labor relations, treatment, promotion, benefits and retirement of the staff to safeguard their interests.

The Group strictly complied with the PRC laws and regulations and policies associated with social insurance, and made full contributions to various social insurance and housing provident fund for all the staff in a timely manner.

2. Health and safety

Employees are the most important wealth and resources of the Group, therefore, the health and safety of employees are always the top priority of the Group. The Group is committed to protecting the employees with production safety while endeavour to protect and care about their healthy and to provide a safe, healthy and protected workplace.

The Group established a comprehensive management system in occupational health and safety, strictly complied with the regulations of occupational health and safety in mainland China and Hong Kong, and laid a solid foundation for safe operation. As at 31 December 2021, the Group did not experience any significant safety accident during the operation.

B. 社會

僱傭及勞工常規

1. 僱傭

僱員被視為本集團最大及具價值的資產和競爭優勢的核心，同時為本集團提供不斷創新的原動力。本集團提供優厚的薪酬福利及推行全面表現評核計劃，以獎勵及表揚表現優秀的員工，並透過適當培訓及提供機會協助彼等在集團內發展事業及晉升。同時，為向僱員提供理想及公平的工作環境及保障僱員之身心健康，本集團慎重考慮僱員有關提升工作效率及和諧工作氣氛的所有寶貴意見，從而為本集團建立起團結和諧的專業團隊。

本集團嚴格執行中國及香港之相關法規條例，制訂並嚴格執行相關管理制度及辦法，對員工的聘用、勞動關係、待遇、升遷、福利、退休等方面作出明確規定，致力保障員工的權益。

本集團嚴格按照中國有關社會保險的法律法規和政策規定，為全體員工按時足額繳納各項社會保險及住房公積金。

2. 健康與安全

員工是本集團最重要的財富和資源，因此本集團始終把員工的健康與安全放在首位，集團以安全生產保護員工，致力於為員工提供健康關懷，亦為員工提供安全、健康及受保障的工作環境。

本集團在職業健康安全設立了完善的管理制度，嚴格遵照中國內地及香港之職業健康安全法例，為安全營運奠定穩固基礎。於二零二一年十二月三十一日，本集團於營運時並未發生重大的安全事故。



3. Development and training

The Group adopts the principle of unified management and stratified training for the education and training of its staff. Upon joining the Group, new employees must participate in pre-service training focusing on the Group's corporate culture, corporate policies and goals, production safety, necessary skills, etc. A series of tailor-made training courses are provided to senior management and middle management on anti-corruption practices for leaders as well as trainings for middle and senior management of listed companies. The Group will evaluate the training effects subsequently, so as to enhance the pertinence and effectiveness of training, which will further enhance the technical skills and professional quality of the Group's employees of each level achieving satisfactory results.

4. Labour standards

There is a clear requirement on the age of applicants in the recruitment management system of the Group. The Group will review and check the identification information of applicants during the recruitment process and absolutely no child labor will be employed. Applicants should provide documents of educational background and working experience for our verification when they report to work. Any suspected applicants providing false documents of educational background and working experience will not be employed. The Group strives to create a safe, healthy and comfortable working environment for the employees, and provide labor protection, reasonable remuneration and various benefits to the employees. The Group enters into an employment contract with each of the employees in accordance with relevant regulations in the PRC and in Hong Kong, and forbids any kind of forced labor.

Operational practices

5. Supply chain management

Supply chain management is always one of the key links in the Group's quality control system. The Group focuses on the risk management of product quality and keeps a close eye on signals of quality and safety crisis of its medicines. Attaching great importance to product compliance, the Group organizes self-inspections and rectifications in a timely manner to ensure product quality.

3. 發展及培訓

本集團對員工的教育培訓採取統一管理，分級培訓的原則。新員工入職之日起即接受集團企業文化、方針目標、安全生產和必須崗前培訓等。針對高級管理人員及中層管理人員進行了領導幹部廉潔從業、上市公司中高層管理者培訓等一系列培訓，同時對培訓成效進行評價，加強培訓的針對性和有效性，進一步提升了本集團各級員工的技能和專業素養，取得了良好的效果。

4. 勞工準則

本集團招聘管理制度中對招聘人員的年齡有明確要求，在招聘過程中審查及核對應聘者的身份證明資料，絕不聘用任何童工。應聘者於應聘時亦需要提供相關的學歷及工作證明文件進行核對，懷疑持有虛假學歷及工作經驗者將不會獲聘用。本集團致力為員工營造安全、健康及舒適的工作環境，並提供勞動保護及向員工支付合理薪酬和提供各項福利。本集團按照中國及香港之相關法規條例與每一位員工訂立僱用合約，並禁止一切強制勞動。

營運慣例

5. 供應鏈管理

供應鏈管理始終是本集團質量控制體系重要環節之一。本集團注重產品質量的風險管理，關注藥品質量安全的危機信號，及時自檢自查，高度重視產品的合規性。



To ensure the quality of the purchased raw materials, auxiliary ingredients and packaging materials, the Group has established a supplier management system in strict compliance with the Law of the PRC on the Administration of Pharmaceuticals, GMP, and other relevant laws and regulations. A standardised management system is implemented on the procurement of materials under a comparatively well-established management system.

The Group also carries out long-term quality monitoring and regular reviews on all suppliers. In case of a significant change in supplier qualification or serious quality issue occurs, the Group may suspend the delivery of the supplier in question immediately to ensure the quality of the medicine of the Group.

6. Product responsibility

The Group is committed to ensuring product safety. Especially, as most of our products are pharmaceuticals, product quality and safety are undoubtedly the top priority of the Group.

The Group always sticks to strict product quality control throughout the production process. The Group's quality control is executed primarily in accordance with relevant requirements of GMP quality management system.

The Group has formulated a complete set of quality inspection management standards covering traditional Chinese medical materials, auxiliary ingredients, packaging materials, semi-finished and finished products, and sets out requirements on various test objects, test methods and test contents. During the year, the Group had no products recall due to quality.

Meanwhile, the Group carried out advertisement promotion in accordance with the law, further safeguarded the rights and interests of consumers, ensured the legal compliance of the Group's advertisement promotion and stringently prohibited any acts that would cause damage to the image of the Group and the brand, such as illegal advertisements.

為確保本集團所有原料、輔料及包材的供應質量，本集團嚴格按照《中華人民共和國藥品管理法》、GMP及其他相關法律法規的要求，制定了供貨商管理制度，對物料採購推行標準化管理，建立了日趨完善的管理體系。

本集團亦會對所有供貨商進行長期質量監控及定期評審，如發現供貨商資質有重大變動或出現嚴重質量問題，本集團立即停止該供貨商之供貨，確保本集團藥品質量安全。

6. 產品責任

本集團致力於確保產品安全，特別是集團的產品大多屬藥品，保證產品質量及安全無疑是集團工作的重中之重。

在生產過程中，本集團始終堅持嚴格的產品質量控制。本集團的質量控制主要根據GMP質量管理體系的相關要求執行。

本集團制定了各項質量檢驗管理標準，包括中藥材、輔料、包材、半成品及成品，對各種檢驗對象、檢驗方法與檢驗內容作出了詳細規定。年內，本集團未出現因產品質量問題而召回產品之情形。

同時，本集團依法進行廣告宣傳，進一步保障消費者權益、確保集團廣告宣傳合法合規，嚴格遏制違法廣告等有損集團及品牌形象的情形發生。



7. Anti-corruption

All of the Group's operations are in compliance with local and national legislation on standards of conduct, such as with the Prevention of Bribery Ordinance in Hong Kong and relevant legislation on anti-corruption and bribery in mainland China.

The Group requires employees to strictly conform to code of business ethics and forbids any corruption bribe behavior as stipulated in the employment contracts. In case of any conflict of interest, it must be reported to the Group's management immediately. Employees, who engage in business operations and represent the Group's professional image, are strictly prohibited to use business opportunities or power for personal interest or benefit.

Community

8. Community investment

The Group always seeks to become a positive momentum in the communities in which it operates and maintains close communications and interactions with the communities in order to contribute to local development.

The Group believes that the creation of a beautiful and peaceful community relies on the cooperation of people, corporations and the government. By working together with various community partners, the Group believes it can bring a tremendous impact on the sustainable development of the communities in which it operates.

The Group will also actively encourage the staff to volunteer their time and skills to benefit local communities. It provides the employees with the opportunities to explore more issues of the society and environment and reinforce the Group's corporate values.

7. 反貪污

本集團所有的業務均遵守當地及國家法例的操守準則，例如香港的防止賄賂條例以及中國內地相關反貪腐法例。

在僱用合約中，本集團要求員工嚴格遵守商業道德準則，杜絕任何貪污及賄賂行為。如有利益衝突，需要及時向本集團管理層申報。參與業務營運及代表本集團的專業形象的員工，嚴禁利用商機或職權取得個人利益或好處。

社區

8. 社區投資

本集團努力尋求成為營運所處社區的正面力量，並一直與小區維持密切溝通和互動，為社區發展作出貢獻。

本集團相信創造一個美好平和的社區需要市民、企業及政府共同的參與。透過與不同的社區夥伴通力合作，本集團相信可為營運所處社區的可持續發展帶來重大影響。

本集團亦將積極鼓勵員工無償付出時間和技能，以惠及本地社區，借此給予僱員機會瞭解更多社會及環境問題，及增強本集團企業價值。

吉林省輝南長龍生化藥業股份有限公司
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
www.jlchanglong.com